Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Molecular Diagnostics Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 07-06-2019
Market Overview
The global molecular diagnostics market was valued at USD 7,854.45 million in 2018, and is estimated to be valued at USD 13,340.35 million by 2024, while witnessing a CAGR of 9.23% during the forecast period, 2019-2024. Factors that are responsible for the growth of the market include large outbreaks of bacterial and viral epidemics in the world, increasing demand for point-of-care diagnostics, recent advancements in pharmacogenomics, and rapidly evolving technology.
Molecular diagnostics is considered to be the best method to identify and characterize a microorganism. An effective test must be precise, rapid, and also be able to measure the infectious burden. Better testing quickly identifies the organism’s strain and drug susceptibility, thus, reducing the delay in finding the right antibiotic. Technological advancements, like a polymerase chain reaction (PCR), have also made it possible to identify the antimicrobial resistance genes and provide public health information, such as strain characterization by genotyping. The infectious disease segment currently records the highest growth in the molecular diagnostics market.
Scope of the Report
Molecular diagnostic tests detect specific sequences in DNA or RNA (including single nucleotide polymorphisms (SNP), deletions, rearrangements, insertions, and others), which may or may not be associated with diseases. Molecular diagnostics has been revolutionized over the past few decades. Currently, it is the driving force behind the transformation in healthcare, thus, leading to innovations in the field of molecular biology. These include next-generation sequencing, microarray technologies, liquid biopsies, early cancer detection, direct-to-consumer testing, and point-of-care assays.
Key Market Trends
Instruments Sub-segment is Expected to Hold the Largest Market Share in the Product Segment
In the product segment of the global molecular diagnostics market, the instruments sub-segment is believed to have the largest market size and is expected to witness a CAGR of 9.13% during the forecast period.
Molecular diagnostics plays a vital role in the assessment of disease prognosis and therapy response, as well as in the detection of minimal residual disease. In the past decade, molecular diagnostics has grown, due to advances in the chemistries and instrumentation, including automation, integration, throughput, and the ability to use the instrumentation in a random-access mode.
Some of the sophisticated instruments used in this market are High-performance Liquid Chromatography (HPLC), Mass Spectrometry (MS), and Nuclear Magnetic Resonance (NMR), along with real-time PCR, Enzyme-linked ImmunoSorbent Assay (ELISA), RadioImmunoAssay (RIA), lateral flow devices, patient safety syringes, point-of-care testing devices, and others.
North America Dominates the Market and is Expected to do the Same over the Forecast Period
North America currently dominates the molecular diagnostics market and is expected to continue its stronghold for a few more years. The United States accounts for the largest market share in the overall North American molecular diagnostics market. Molecular diagnostics has played a vital role in changing the face of disease diagnostics and assuring speedy detection and accurate care for critically ill patients. The increase in per capita health expenditures, the advancement in healthcare infrastructure, and the increase in the number of infectious diseases and cancer cases in the United States have led to a shift in trend from the traditional diagnostic methods to molecular diagnostics.
In addition, rising technological advancements, increasing entry of new players, and speedy adoption of advanced molecular diagnostics, are helping in the growth of the market in the United States.
Competitive Landscape
The global molecular diagnostics market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to small companies are increasing their market presence by introducing new devices with fewer prices. Companies, like Abbott Laboratories, F. Hoffmann-la Roche Ltd, Hologic Corporation, Danaher Corporation, and Agilent Technology, hold substantial shares in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Large Outbreaks of Bacterial And Viral Epidemics in the World
4.2.2 Increasing Demand for Point-of-care Diagnostics
4.2.3 Recent Advancements in Pharmacogenomics
4.2.4 Rapidly Evolving Technology
4.3 Market Restraints
4.3.1 Limited Budgets for R&D and Economic Slowdown
4.3.2 Need for High-complexity Testing Centers
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Technology
5.1.1 In Situ Hybridization
5.1.2 Chips and Microarrays
5.1.3 Mass Spectrometry (MS)
5.1.4 Sequencing
5.1.5 PCR
5.1.6 Other Technologies
5.2 Application
5.2.1 Infectious Disease
5.2.2 Oncology
5.2.3 Pharmacogenomics
5.2.4 Microbiology
5.2.5 Genetic Disease Screening
5.2.6 Human Leukocyte Antigen Typing
5.2.7 Blood Screening
5.3 Product
5.3.1 Instruments
5.3.2 Reagents
5.3.3 Other Products
5.4 End User
5.4.1 Hospitals
5.4.2 Laboratories
5.4.3 Other End Users
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 F. Hoffmann-la Roche Ltd
6.1.2 Illumina, Inc.
6.1.3 Hologic Corporation
6.1.4 Agilent Technologies / Dako
6.1.5 Qiagen
6.1.6 Myriad Genetics
6.1.7 BD (Becton, Dickinson And Company)
6.1.8 Abbott Laboratories
6.1.9 Cepheid Inc.
6.1.10 Genomic Health Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Technology
In Situ Hybridization
Chips and Microarrays
Mass Spectrometry (MS)
Sequencing
PCR
Other Technologies
Application
Infectious Disease
Oncology
Pharmacogenomics
Microbiology
Genetic Disease Screening
Human Leukocyte Antigen Typing
Blood Screening
Product
Instruments
Reagents
Other Products
End User
Hospitals
Laboratories
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Precision Medicine Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 116 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 116 pages
- Published: 07-06-2019
Market Overview
The global precision medicine market was valued at USD 48,554.1 million in 2018, and is estimated to be valued at USD 84,590.21 million in 2024, witnessing a CAGR of 9.7%. The key factors propelling the growth of this market are increasing online collaborative forums, increasing efforts to characterize genes, and advancements in cancer biology. The fundamental concept of precision medicine is to understand the genetic makeup and difference at a population level, and further at an individual level, in order to customize a drug that targets a particular gene type. Hence, sequencing or characterizing genes is the most important method to gain information about genes and their possible mutations.
The functional characterization of identified genomic mutations, coupled with comprehensive clinical data available in electronic health records, has the potential to provide compelling evidence to implicate novel disease and/or drug-associated mutations in phenotypically well-characterized patients. There have been increasing efforts made by both the government and private players to establish databases that contain information of characterized genes of a large population. Some countries are establishing a national repository of genetic information to accelerate the research in precision medicine. Methods, such as meta-analysis, transcriptome data analysis, and RNA-seq data analysis, are employed to characterize genes, generally.
Scope of the Report
Precision medicine, a combination of molecular biology techniques and systems biology, is an emerging approach for disease treatment and prevention. The market growth for this approach is gaining momentum, as it takes into account individual variability in genes, environment, and lifestyle, for each person, while developing drugs and vaccines.
Key Market Trends
Oncology is Expected to hold the Highest Market Share in the Application Segment
In the application segment of the precision medicine market, oncology is believed to have the largest market size and is expected to witness a CAGR of 10.3%, during the forecast period.
Precision medicine applications are primarily directed toward better treatment against oncological diseases, with an estimated more than 30% market dominance over other segments. As per the data reported in clinicaltrials.gov, the United States and some European countries are the major hubs for conducting and recruiting patient pool for precision medicine applications in oncology, globally. The high support from the government through funding and rapid growth of genomic analysis are expected to augment the growth of the precision medicine market at a fast rate, over the forecast period.
North America Dominates the Market and is Expected to do the Same in the Forecast Period
North America currently dominates the market for precision medicine, and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. Former President Barack Obama, in 2015, unveiled the Precision Medicine Initiative (PMI), a bold new enterprise to revolutionize medicine and generate the scientific evidence needed to move the concept of precision medicine into every-day clinical practice.
The Precision Medicine Initiative also includes ongoing efforts through the Department of Veteran’s Affairs (VA), which has enrolled over 450,000 veterans in the Million Veteran Program (MVP), a participant-driven research cohort. The Food and Drug Administration (FDA), the Office of the National Coordinator for Health IT, and the Office for Civil Rights announced in February 2016 that they will build research and data capacity, technical tools, and policies to accelerate precision medicine, thereby, boosting the precision medicine market in the country.
Competitive Landscape
The precision medicine market is highly competitive and consists of several major players, along with a number of smaller companies. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new technologies with affordable prices. Companies, like Medtronic PLC, Pfizer Inc., Novartis AG, Qiagen, and Teva Pharmaceuticals, hold substantial shares in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Online Collaborative Forums
4.2.2 Increasing Efforts to Characterize Genes
4.2.3 Advancement in Cancer Biology
4.3 Market Restraints
4.3.1 Perils of Data Sharing
4.3.2 Shift From Treatment-based To Preventive Healthcare
4.3.3 Declining Trends in FDA Pharmacotherapy Approval Rate
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Technology
5.1.1 Big Data Analytics
5.1.2 Bioinformatics
5.1.3 Gene Sequencing
5.1.4 Drug Discovery
5.1.5 Companion Diagnostics
5.1.6 Other Technologies
5.2 By Application
5.2.1 Oncology
5.2.2 CNS
5.2.3 Immunology
5.2.4 Respiratory
5.2.5 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Biocrates Life Sciences AG
6.1.2 Nanostring Technologies
6.1.3 Intomics
6.1.4 Pfizer Inc.
6.1.5 Eagle Genomics Ltd
6.1.6 Teva Pharmaceutical Industries Ltd
6.1.7 Laboratory Corporation Of America Holdings
6.1.8 Medtronic
6.1.9 Novartis AG
6.1.10 Qiagen NV
6.1.11 Quest Diagnostics Incorporated
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Technology
Big Data Analytics
Bioinformatics
Gene Sequencing
Drug Discovery
Companion Diagnostics
Other Technologies
By Application
Oncology
CNS
Immunology
Respiratory
Other Applications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Biopharmaceuticals Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 114 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 114 pages
- Published: 07-06-2019
Market Overview
The global biopharmaceuticals market was valued at USD 237,250.8 million in 2018, and is estimated to be valued at USD 388,997.3 million in 2024, witnessing a CAGR of 8.59%. The market growth is attributed to the growing acceptance for biopharmaceuticals due to their ability to treat previously untreatable diseases, resulting in huge market demand for biopharmaceuticals.
Biopharmaceuticals offer several benefits, such as highly effective and potent action, fewer side effects, and the potential to actually cure diseases rather than merely treat the symptoms, which have significantly increased the demand for biopharmaceutical products.
Biopharmaceuticals have reduced the number of deaths due to cancer and HIV/AIDS in the past decade, which has led to an increase in the adoption of biopharmaceuticals in the global market.
Biopharmaceuticals have given an alternative to the previously less effective and sometimes unsafe treatments, and it allows clinicians to tailor treatments to the specific medical problems experienced by each patient.
Scope of the Report
For the scope of the report, the term biopharmaceutical refers to any biologically synthesized molecule that is used to treat or manage disorders.
Key Market Trends
Monoclonal Antibodies are Expected to have the Largest Market Size
Among the given segments, monoclonal antibodies are believed to have the largest market size. This can be attributed to the growing research done with the help of monoclonal antibodies. On the other hand, the recombinant enzymes segment is expected to show rapid growth during the forecast period.
Monoclonal antibodies (mAbs) find their application in the areas of cancer treatment. Their use is becoming prevalent in developed countries, such as the United States and the United Kingdom. The mAb drugs in oncology are gaining momentum and growing at a decent pace. The segment is dominating the market currently, and the trend is expected to be followed in the future.
The recombinant enzymes, such as Enterokinase, are gaining attraction because of their efficacy in the digestion of the dietary proteins. Over the years, 100% native protein sequences have been produced using Enterokinase. This application has improved the market scope for this particular enzyme in the recent years.
North America is Expected to Dominate the Biopharmaceuticals Market
North America currently dominates the market for biopharmaceuticals, and is expected to continue its stronghold for a few more years. Asia-Pacific is expected to increase its market share in the future owing to increase in the prevalence of diseases, such as diabetes and cancer, along with the regulatory framework that is feasible for the approval of biopharmaceuticals in the region. The United States holds the majority of the market in the North American region; this is due to the increasing prevalence of chronic diseases. In addition, there is a rise in per capita health expenditure in the country that is expected to increase over the forecast period, owing to the decrease in the unemployment rate.
Competitive Landscape
The biopharmaceuticals market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancement and product innovation, mid-size to smaller companies are increasing their market presence by introducing new products with less prices. Companies, like Amgen Inc., Eli Lily & Company, Johnson & Johnson, and Pfizer Inc. hold a significant share in the biopharmaceuticals market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Acceptance for Biopharmaceuticals
4.2.2 Ability of Biopharmaceuticals to Treat Previously Untreatable Diseases
4.2.3 Huge Market Demand
4.3 Market Restraints
4.3.1 Increasing Demand for Affordable Biopharmaceuticals
4.3.2 High-end Manufacturing Requirements
4.3.3 Complicated and Cumbersome Regulatory Requirements
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Monoclonal Antibodies
5.1.1.1 Anti Cancer Monoclonal Antibodies
5.1.1.2 Anti-inflammatory Monoclonal Antibodies
5.1.1.3 Other Monoclonal Antibodies
5.1.2 Recombinant Growth Factors
5.1.2.1 Erythropoietin
5.1.2.2 Granulocyte Colony Stimulating Factor
5.1.3 Purified Proteins
5.1.3.1 Leukemia Inhibitory Factor (LIF)
5.1.3.2 P53 Protein
5.1.3.3 P38 Protein
5.1.3.4 Other Purified Proteins
5.1.4 Recombinant Proteins
5.1.4.1 Serum Albumin
5.1.4.2 Amyloid Protein
5.1.4.3 Defensin
5.1.4.4 Transferrin
5.1.5 Recombinant Hormones
5.1.5.1 Recombinant Hormones
5.1.5.2 Recombinant Insulin
5.1.5.3 Other Recombinant Hormones
5.1.6 Vaccines
5.1.6.1 Recombinant Vaccines
5.1.6.1.1 Cancer Vaccines
5.1.6.1.2 Malaria Vaccines
5.1.6.1.3 Ebola Vaccine
5.1.6.1.4 Hepatitis-b Vaccine
5.1.6.1.5 Tetanus Vaccine
5.1.6.1.6 Diptheria Vaccine
5.1.6.1.7 Cholera Vaccine
5.1.6.1.8 Other Vaccines
5.1.6.2 Conventional Vaccines
5.1.6.2.1 Polio Vaccine
5.1.6.2.2 Pox Vaccine
5.1.6.2.3 Other Conventional Vaccines
5.1.6.3 Recombinant Enzymes
5.1.6.3.1 Enterokinase
5.1.6.3.2 Cyclase
5.1.6.3.3 Caspase
5.1.6.3.4 Cathepsin
5.1.6.4 Cell and Gene Therapies
5.1.6.4.1 Allogeneic Products
5.1.6.4.2 Autologous Products
5.1.6.4.3 Acellular Products
5.1.6.5 Other Product Types
5.1.6.5.1 Blood Factors
5.1.6.5.2 Other Product Types
5.1.7 Synthetic Immunomodulators
5.1.7.1 Cytokines, Interferones, Interleukins
5.1.7.2 Tumor Necrosis Factor (TNF)
5.2 By Therapeutic Application
5.2.1 Oncology
5.2.2 Inflammatory and Infectious Diseases
5.2.3 Autoimmune Disorders
5.2.4 Metabolic Disorders
5.2.5 Hormonal Disorders
5.2.6 Disease Prevention
5.2.7 Cardiovascular Diseases
5.2.8 Neurological Diseases
5.2.9 Other Diseases
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 United Kingdom
5.3.2.2 Germany
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 India
5.3.3.2 China
5.3.3.3 Japan
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbvie Inc.
6.1.2 Amgen Inc.
6.1.3 Bristol-Myers Squibb Company
6.1.4 Eli Lily & Co.
6.1.5 Johnson & Johnson
6.1.6 Novartis AG
6.1.7 Novo Nordisk Inc.
6.1.8 Pfizer Inc.
6.1.9 GlaxoSmithKline PLC
6.1.10 Roche Holding AG
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product Type
Monoclonal Antibodies
Anti Cancer Monoclonal Antibodies
Anti-inflammatory Monoclonal Antibodies
Other Monoclonal Antibodies
Recombinant Growth Factors
Erythropoietin
Granulocyte Colony Stimulating Factor
Purified Proteins
Leukemia Inhibitory Factor (LIF)
P53 Protein
P38 Protein
Other Purified Proteins
Recombinant Proteins
Serum Albumin
Amyloid Protein
Defensin
Transferrin
Recombinant Hormones
Recombinant Hormones
Recombinant Insulin
Other Recombinant Hormones
Vaccines
Recombinant Vaccines
Cancer Vaccines
Malaria Vaccines
Ebola Vaccine
Hepatitis-b Vaccine
Tetanus Vaccine
Diptheria Vaccine
Cholera Vaccine
Other Vaccines
Conventional Vaccines
Polio Vaccine
Pox Vaccine
Other Conventional Vaccines
Recombinant Enzymes
Enterokinase
Cyclase
Caspase
Cathepsin
Cell and Gene Therapies
Allogeneic Products
Autologous Products
Acellular Products
Other Product Types
Blood Factors
Other Product Types
Synthetic Immunomodulators
Cytokines, Interferones, Interleukins
Tumor Necrosis Factor (TNF)
By Therapeutic Application
Oncology
Inflammatory and Infectious Diseases
Autoimmune Disorders
Metabolic Disorders
Hormonal Disorders
Disease Prevention
Cardiovascular Diseases
Neurological Diseases
Other Diseases
Geography
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
Asia Pacific
India
China
Japan
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Ion Chromatography Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 10-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 10-06-2019
Market Overview
The growth of the global ion chromatography market is due to the increasing use of ion-exchange chromatography for purification, along with the increasing demand for monoclonal antibodies, which is a primary driver for the market. The current market is also growing due to the increasing adoption of ion-exchange techniques in the food, beverage, and water industries. To check content, quality, or safety, ion chromatography is increasingly being used in various industries. The ion-exchange technique is also being used to check the presence or amount of ingredients in a sample. The high cost of chromatography instruments and the lack of skilled personnel to handle the equipment are hindering the growth of the ion chromatography market.
Scope of the Report
This report estimates the global ion chromatography market. It incorporates a detailed analysis of technology, which includes ion-exchange chromatography, ion-exclusion chromatography, and ion-pair chromatography. Ion chromatography is a well-established technique for the analysis of anions and cations in liquid, gaseous, and solid samples. Organizations, such as the ISO, US EPA, ASTM, and AOAC have established their standards on regulatory methods of analysis using this technique. Currently, electrochemical and spectrometric methods are the two detection methods applied in ion chromatography.
Key Market Trends
Ion-exchange Chromatography Segment is Expected to Exhibit Fastest Growth Rate Over the Forecast Period
There are two types of ion-exchange chromatography techniques, based on the nature of charge present on the ion. They are anion exchange chromatography and cation exchange chromatography. Ion exchange resins are useful as carriers for medicinal materials and in slow release applications. Cholestyramine, a dried and ground strong base anion resin, is used in binding the bile acid for reducing blood cholesterol. The usage of this ion exchange in the medical field is increasing, and thus, driving the market growth.
One of the main advantages of ion exchange is that there is only one interaction involved in the separation, the analytical species interacting with the stationary phase; while the downside of ion-exchange chromatography is the high cost of these columns. The ion-exchange chromatography market share is dominant, due to a wide range of applications and associated markets. This market share is expected to increase further during the forecast period.
North America Captured the Largest Market Share and is Expected to Retain its Dominance
In the United States, ion chromatography is used for many applications. Ion chromatography (IC) has proven to be an effective technology for final production testing, pharmaceutical applications, environmental monitoring, food testing, and other applications. The United States Pharmacopeia (USP) is a non-government not-for-profit organization that supports itself through the sale of books (USP-NF and other publications) and reference standards. USP sets standards for the use of ion chromatography in pharmaceutical applications. Many organizations, such as USEPA (United States Environmental Protection Agency), ASTM (American Society for Testing and Materials), and AOAC (Association of Official Analytical Chemists) are some of the additions to the market in the United States. These organizations also develop standards or regulatory methods of analysis for various applications of ion chromatography.
Competitive Landscape
Agilent Technologies, Bio-Rad Laboratories Inc., GE Healthcare, Metrohm AG, and Mitsubishi Chemical Corporation are some of the major players in the ion chromatography market that are disrupting the market by launching several new products.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Academic and Commercial R&D Spending on Pharmaceuticals
4.2.2 Increasing Use of Ion Chromatography Technique in Purifying Monoclonal Antibodies (MABS)
4.2.3 Increasing Use of Ion Chromatography Technique in the Food, Beverage, and Water Industries
4.2.4 Technological Advancements in Ion Chromatography
4.3 Market Restraints
4.3.1 High Cost of Instruments
4.3.2 Lack of Skilled Personnel to Handle Equipment
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Technology
5.1.1 Ion-exchange Chromatography
5.1.2 Ion-exclusion Chromatography
5.1.3 Ion-pair Chromatography
5.2 Application
5.2.1 Environmental Testing
5.2.2 Pharmaceutical Industry
5.2.3 Food Industry
5.2.4 Chemicals Industry
5.2.5 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Agilent Technologies Inc.
6.1.2 Bio-Rad Laboratories Inc.
6.1.3 GE Healthcare
6.1.4 Metrohm AG
6.1.5 Mitsubishi Chemical Corporation
6.1.6 Perkin Elmer Inc.
6.1.7 Shimadzu Corporation
6.1.8 Thermo Fisher Scientific
6.1.9 Tosoh Corporation
6.1.10 Waters
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Technology
Ion-exchange Chromatography
Ion-exclusion Chromatography
Ion-pair Chromatography
Application
Environmental Testing
Pharmaceutical Industry
Food Industry
Chemicals Industry
Other Applications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Acne Therapeutics Market- Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 07-06-2019
Market Overview
The key factors propelling the growth of the acne therapeutics market are increasing sedentary lifestyles and unhealthy lifestyles, the rise in disposable income of consumers, increasing awareness about upcoming trends in acne treatments, and high prevalence of acne, globally.
The diet and nutrient intake determine the overall health of an individual. The food that is high in refined carbohydrates increases insulin, which results in hormonal problems, promoting acne formation.
More than 90% of the world’s population is found to be affected by acne at some point in their life. In the United States, there are 60 million suffering from acne problems. This includes all grades of acne, from the mild, occasional breakout to more severe conditions. Of the 60 million, 20% have some form of acne bad enough that it results in scarring of the skin. Therefore, there is an increasing adoption of acne cure products, which helps in driving the overall market.
In addition, rapid economic growth has also led to a substantial increase in the disposable incomes of middle-class people. With this increasing income, people are ready to spend more on their facial looks. Thus, the market for acne therapeutics is projected to grow rapidly over the forecast period.
Scope of the Report
As per the scope of the report, acne is a chronic inflammatory skin disease commonly affecting the adolescent and adult populations. Abnormal hormone production is found to be the key causative factor. The increasing use of acne medications is being indicated for its treatment. These include several prescriptions and over-the-counter medicines, such as retinoids, isotretinoin, antibiotics, salicylic acid, benzoyl peroxide, and oral contraceptives, among others. However, the development of effective therapeutics, with lesser side effects and high potential in untapped markets, is expected to provide growth opportunities to the overall market.
Key Market Trends
Topical is the Segment Under Administration that is Expected to Grow the Fastest
The utilization rate of topical medications for acne treatment is high, owing to the high availability of these acne products, with a high success rate and lesser side effects. These agents are directly applied on the skin and need to be used continuously for longer periods of time, from several weeks to months, to get effective result. Therefore, the preference for topical treatment is more, as compared to the oral mode of therapeutic administration. These oral medications are recommended as systemic therapies, after topical treatments fail to evoke a response.
Asia-Pacific Holds the Fastest Growth and is Expected to follow the Same Trend over the Forecast Period
Asia and Pacific is expected to be the fastest-growing region, due to increasing sedentary lifestyles and unhealthy food habits. Prosperity and a faster pace of life have changed the Chinese eating habits. Eating too much with high amounts of fat and calories and exercising less have led to an increase in obesity and acne problems. However, Asia-Pacific is expected to register the highest CAGR, due to the increase in affordability, surge in healthcare expenditure, and rise in awareness about safe acne medication products.
Competitive Landscape
There are many players in the market coming up with new products for acne treatment. Allergan PLC, Valeant Pharmaceutical International Inc., Bayer AG, and Galderma (Nestle Skin Health) are some of the major players in the acne therapeutics market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Sedentary Lifestyle and Unhealthy Food Habits
4.2.2 Rise in Disposable Income of Consumers
4.2.3 Increasing Awareness About Current and Upcoming Acne Treatments
4.2.4 High Global Acne Prevalence
4.3 Market Restraints
4.3.1 Safety Issues Regarding the Products
4.3.2 Entry of Generics in the Acne Treatment Drug Market
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Treatment
5.1.1 Therapeutics
5.1.1.1 Retinoid
5.1.1.2 Antibiotics
5.1.1.3 Hormonal Agents, Combination Medications, Anti-inflammatory
5.1.1.4 Other Agents
5.1.2 Other Treatments
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Topical
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Cipher Pharmaceuticals
6.1.2 Glaxosmithkline PLC
6.1.3 Bayer AG
6.1.4 Teva Pharmaceuticals
6.1.5 Ranbaxy
6.1.6 Allergan
6.1.7 F. Hoffmann-la Roche Ltd
6.1.8 Nestle SA (Galderma)
6.1.9 Johnson & Johnson
6.1.10 Valeant Pharmaceuticals International Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Treatment
Therapeutics
Retinoid
Antibiotics
Hormonal Agents, Combination Medications, Anti-inflammatory
Other Agents
Other Treatments
By Route of Administration
Oral
Topical
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Antibiotics Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 116 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 116 pages
- Published: 07-06-2019
Market Summary
The global antibiotics market was valued at USD 42,653.89 million in 2018, and is estimated to be valued at USD 56,369.92 million in 2024, witnessing a CAGR of 4.7%. Certain factors that are driving the market growth include the emergence of anti-MRSA drugs, development of generic drugs, and vulnerable aging population.
A company that initially produced the patented drug tries to generate maximum revenue before the patent expires. Once the patent expires, there will be many competitors who begin manufacturing the generic formulations. They have the same composition and same pharmacological activities as of the original drug. Almost 80% of the prescription antibiotics are generic. As a result of this, the price is reduced. More people can afford drugs, thus, resulting in improved healthcare outcomes. However, indiscriminate drug usage also leads to drug resistance and other complications.
Scope of the Report
As per the scope of the report, antibiotic medicines are among the most prescribed courses worldwide, in fighting bacterial infections, primarily in outpatient settings.
Key Market Trends
Carbapenems are Expected to Show the Rapid Growth of in the Future.
The cephalosporin segment is expected to account for the largest market size during the forecast period. Carbapenems are expected to witness the highest CAGR of around 5.9% during the forecast period.
The rising threat of drug resistance and a weak pipeline of new molecules are leading to the development of combinational formulations. For instance, in countries, like India, the emergence of multi-drug-resistant tuberculosis (TB) is a major factor driving the R&D expenditures. Methicillin-resistant Staphylococcus aureus (MRSA) is another bacterium responsible for several infections in humans that are difficult to treat. The MRSA infection is difficult to treat with standard antibiotics, such as penicillins (methicillin, dicloxacillin, nafcillin, and oxacillin), and the cephalosporins. In 2014, the US Food and Drug Administration (FDA) approved four new antibiotics for the treatment of infections caused by gram-positive bacteria, including MRSA.
North America is Expected to Dominate the Market in the Forcasted Period
North America currently dominates the market for antibiotics and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the increased adoption of antibiotics. The United States holds the majority of the market in the North American region, due to the fact that the United States has the highest antibiotic prescribing rate in the North American region. In addition, there is a rise in per capita health expenditure in the country, which is expected to increase over the forecast period, owing to decrease in the unemployment rate.
Competitive Landscape
The antibiotics market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence, by introducing new products with less prices. Companies, like Glaxosmithkline, Pfizer PLC, Bayer AG, Novartis AG, and Abbott Inc., hold significant market shares in the antibiotics market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Emergence of Anti-MRSA/VRE Drugs
4.2.2 Development of Generic Drugs
4.2.3 Vulnerable Aging Population
4.3 Market Restraints
4.3.1 Antibiotic Resistance
4.3.2 Fewer Companies Involved in Active Research
4.3.3 Time Taken for Regulatory Approval
4.4 Industry Attractiveness of Porter’s Five Forces Analysis
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Cephalosporins
5.1.2 Penicillins
5.1.3 Fluroquinilones
5.1.4 Macrolides
5.1.5 Carbapenems
5.1.6 Aminoglycosides
5.1.7 Sulfonamides
5.1.8 Other Product Types
5.2 By Spectrum
5.2.1 Broad-spectrum Antibiotics
5.2.2 Narrow-spectrum Antibiotics
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 France
5.3.2.2 Germany
5.3.2.3 United Kingdom
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 GlaxoSmithKline PLC
6.1.2 Johnson & Johnson Inc.
6.1.3 Merck & Co. Inc.
6.1.4 Pfizer Inc.
6.1.5 Bayer Healthcare AG
6.1.6 Novartis AG
6.1.7 Sanofi SA
6.1.8 Abbott Laboratories
6.1.9 Roche Holding AG
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product Type
Cephalosporins
Penicillins
Fluroquinilones
Macrolides
Carbapenems
Aminoglycosides
Sulfonamides
Other Product Types
By Spectrum
Broad-spectrum Antibiotics
Narrow-spectrum Antibiotics
Geography
North America
United States
Canada
Mexico
Europe
France
Germany
United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America